Belgium-based biopharmaceutical company UCB has announced that it is withdrawing the European marketing authorization application with the European Medicines Agency for Vimpat in the treatment of diabetic neuropathic pain.
UCB has taken this decision based on the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) view that the magnitude of the clinical effect of lacosamide in diabetic neuropathic pain has not been convincingly established.
More
No comments:
Post a Comment